Can you make optimal treatment choices for challenging triple-negative breast cancer (TNBC) cases? Put your TNBC skills to the test in these interactive case challenges. As the third and final activity in the TNBC series, you will navigate through two cases. Education is built into the cases, on practical strategies to meet the treatment needs of diverse patients with TNBC.
Educational Partner: The Academy for Continued Healthcare Learning (ACHL)
Medium: Online Presentation
Commercial Support: Support for this activity has been provided through educational grants from Gilead Sciences Inc.
Sponsored by the University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL).
Overview
Syllabus
At the conclusion of this activity, participants will be able to:
- Discuss new targeted treatment approaches in the setting of triple-negative breast cancer;
- Discuss the role of antibody-drug conjugate therapies and TROP2 for triple-negative breast cancer.
Tags
Related Courses
-
Where do Anti-TROP2 ADCs Factor into Advanced TNBC Care?
-
Early-Stage TNBC: What are the Roles of PARPIs?
-
Improving Breast Cancer Disparities: Treatment
-
Race, Ethnicity, and Breast Cancer: Health Equity Panel Equity Training
-
Improving Breast Cancer Disparities: Screening and Diagnosis
-
Expert Insights - 19th Annual International Ultmann Chicago Lymphoma Symposium
